Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest shareholders are individual investors with 38% ownership, public companies own 30% [Yahoo! Finance]
Lucid Diagnostics (NASDAQ:LUCD) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
Lucid Diagnostics (NASDAQ:LUCD) was downgraded by analysts at
Wall Stree
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum